Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23244
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPoole, Alexis P-
dc.contributor.authorFinnis, Mark E-
dc.contributor.authorAnstey, James-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorBihari, Shailesh-
dc.contributor.authorBiradar, Vishwanath-
dc.contributor.authorDoherty, Sarah-
dc.contributor.authorEastwood, Glenn-
dc.contributor.authorFinfer, Simon-
dc.contributor.authorFrench, Craig J-
dc.contributor.authorGhosh, Angaj-
dc.contributor.authorHeller, Simon-
dc.contributor.authorHorowitz, Michael-
dc.contributor.authorKar, Palash-
dc.contributor.authorKruger, Peter S-
dc.contributor.authorMaiden, Matthew J-
dc.contributor.authorMårtensson, Johan-
dc.contributor.authorMcArthur, Colin J-
dc.contributor.authorMcGuinness, Shay P-
dc.contributor.authorSecombe, Paul J-
dc.contributor.authorTobin, Antony E-
dc.contributor.authorUdy, Andrew A-
dc.contributor.authorYoung, Paul J-
dc.contributor.authorDeane, Adam M-
dc.date.accessioned2020-05-18T06:53:43Z-
dc.date.available2020-05-18T06:53:43Z-
dc.date.issued2020-06-
dc.identifier.citationCritical Care and Resuscitation 2020; 22(2): 133-141-
dc.identifier.issn1441-2772-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23244-
dc.description.abstractContemporary glucose management of intensive care unit (ICU) patients with type 2 diabetes is based on trial data derived predominantly from patients without type 2 diabetes. This is despite the recognition that patients with type 2 diabetes may be relatively more tolerant of hyperglycaemia and more susceptible to hypoglycaemia. It is uncertain whether glucose targets should be more liberal in patients with type 2 diabetes. To detail the protocol, analysis and reporting plans for a randomised clinical trial - the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial - which will evaluate the risks and benefits of targeting a higher blood glucose range in patients with type 2 diabetes. A multicentre, parallel group, open label phase 2B randomised controlled clinical trial of 450 critically ill patients with type 2 diabetes. Patients will be randomised 1:1 to liberal blood glucose (target 10.0-14.0 mmol/L) or usual care (target 6.0-10.0 mmol/L). The primary endpoint is incident hypoglycaemia (< 4.0 mmol/L) during the study intervention. Secondary endpoints include biochemical and feasibility outcomes. The study protocol and statistical analysis plan described will delineate conduct and analysis of the trial, such that analytical and reporting bias are minimised. This trial has been registered on the Australian New Zealand Clinical Trials Registry (ACTRN No. 12616001135404) and has been endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group.-
dc.language.isoeng-
dc.titleStudy protocol and statistical analysis plan for the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial.-
dc.typeJournal Article-
dc.identifier.journaltitleCritical Care and Resuscitation-
dc.identifier.affiliationThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Critical Care Medicine, Auckland District Health Board, Auckland, New Zealanden
dc.identifier.affiliationMedical Research Institute of New Zealand, Wellington, New Zealanden
dc.identifier.affiliationCardiothoracic and Vascular Intensive Care and High Dependency Unit, Auckland District Health Board, Auckland, New Zealanden
dc.identifier.affiliationEndocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, Australiaen
dc.identifier.affiliationDiscipline of Acute Care Medicine, University of Adelaide, Adelaide, SA, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Princess Alexandra Hospital, Brisbane, QLD, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Alice Springs Hospital, Alice Springs, NT, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, St Vincent's Hospital Melbourne, Melbourne, VIC, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, The Alfred Hospital, Melbourne, VIC, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Intensive and Critical Care Unit, Flinders Medical Centre, Adelaide, SA, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Lyell McEwin Hospital, Adelaide, SA, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Western Health, Melbourne, VIC, Australiaen
dc.identifier.affiliationIntensive Care Unit, Northern Health, Melbourne, VIC, Australiaen
dc.identifier.affiliationClinical Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, United Kingdom..-
dc.identifier.affiliationSection of Anaesthesia and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden..-
dc.identifier.orcid0000-0002-1650-8939-
dc.identifier.pubmedid32389105-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Oct 19, 2020

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.